Although no transplantation trials appear to be in progress, one phase II trial is currently underway investigating use of Granulocyte-Macrophage Colony-Stimulating Factor (Sargramostim; GM-CSF) for the mobilization of hematopoietic progenitors in patients with AD (NCT01409915). Here, CSF2 is linked to Alzheimer disease.